Caricamento...
Phase 2 trial of montelukast for prevention of pain in sickle cell disease
Cysteinyl leukotrienes (CysLTs) are lipid mediators of inflammation. In patients with sickle cell disease (SCD), levels of CysLTs are increased compared with controls and associated with a higher rate of hospitalization for pain. We tested the hypothesis that administration of the CysLT receptor ant...
Salvato in:
| Pubblicato in: | Blood Adv |
|---|---|
| Autori principali: | , , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
American Society of Hematology
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7094028/ https://ncbi.nlm.nih.gov/pubmed/32208487 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001165 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|